ERS International Congress, Milan 2017

---

COPD management

Thematic Poster
Chairs: B. Gemicioglu (Istanbul, Turkey), R. Dekhuijzen (Nijmegen, Netherlands), M. van den Berge (Groningen, Netherlands), P. Girodet (Bordeaux, France)

Safety profile of COPD medications in COPD patients with concomitant diabetes mellitus S. Krüger (Dusseldorf, Germany)
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses D. Lipson (Wynnewood, United States of America)
Case series of long-term macrolide therapy effect on eosinophil count in COPD R. Asciak (Oxford, United Kingdom)
Effect of the five-element music therapy based on the midnight-noon ebb-flow theory on Somnipathy Patients with COPD Accompanied by Anxiety. H. Lin (Changchun City, China)
Risk factors for discontinuation of roflumilast in COPD patients C. Rhee (Seoul, Republic of Korea)
Differences in attitudes and knowledge of doctors and nurses towards oxygen prescribing in a district general hospital S. Hussain (Kettering, United Kingdom)
The relationship between symptom scores and medication adherence in stable COPD patients D. Kocakaya (ISTANBUL, Turkey)
The impact of vaccination on the dynamics of bronchial and systemic inflammation in patients with COPD and CHD G. Ignatova (Chelyabinsk, Russian Federation)
The importance of eosinophilic inflammation in COPD exacerbations M. Vargas-Castanho (LISBOA, Portugal)
Combined dual bronchodilator and wearable headset-based exercise training enhance daily activity monitored by wearable watch in COPD> K. Chen (Taipei, Taiwan)
BLOOD EOSINOPHILS AND SMOKING HISTORY AFFECT OUTCOME WITH HIGH DOSE N-ACETYLCYSTEINE TREATMENT IN COPD A. Papi (Ferrara, Italy)
The significance of the adherence to the discharge criteria in patients with acute exacerbation of COPD on early readmission Z. Azzam (Haifa, Israel)
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice. S. Akhmedov (Tashkent, Uzbekistan)
Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes M. Dransfield (Birmingham, United States of America)
Low rate of exacerbations following initiation of LABA/LAMA fixed-dose combinations: An analysis of the DACCORD real life study C. Vogelmeier (Marburg, Germany)
Biomarkers in COPD: Beneficial effects of roflumilast I. Savelikhina (Ivano-Frankivsk, Ukraine)
The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD I. Savelikhina (Ivano-Frankivsk, Ukraine)
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Y. Chen (Waltham, United States of America)
Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease E. Samorukova (Moscow, Russian Federation)
Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study J. Wedzicha (London, United Kingdom)